The antigen CD19 is widely expressed on B-cell malignancies including non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL), thus prompting the use of CAR-T cells targeting CD19 for the treatment of NHL [1]. The gene discussed is CD19; the disease is mantle cell lymphoma.